IMMUNE RESPONSES IN AUTOIMMUNE HEPATITIS: EFFECT OF PREDNISONE AND AZATHIOPRINE TREATMENT: CASE REPORT by Bluth, Martin H. et al.
Int. J. Med. Sci. 2009, 6 
 
 
http://www.medsci.org 
177
I In nt te er rn na at ti io on na al l   J Jo ou ur rn na al l   o of f   M Me ed di ic ca al l   S Sc ci ie en nc ce es s   
2009; 6(4):177-183 
© Ivyspring International Publisher. All rights reserved 
Research Paper 
IMMUNE RESPONSES IN AUTOIMMUNE HEPATITIS: EFFECT OF PREDNISONE AND 
AZATHIOPRINE TREATMENT: CASE REPORT 
Martin H. Bluth1, Stephan Kohlhoff 2,4, Kevin B. Norowitz2, Jonathan I Silverberg3,4, Seto Chice3, M Nowa-
kowski3,4, Helen G. Durkin3,4, Tamar A. Smith-Norowitz 2,4 
 
1.  Deptartment of Pathology, Wayne State University School of Medicine, Detroit, MI 48201, USA; 
2.  Departments of Pediatrics, SUNY Downstate Medical Center, Brooklyn, New York 11203, USA; 
3.  Departments of Pathology, SUNY Downstate Medical Center, Brooklyn, New York 11203, USA; 
4.  Center for Allergy and Asthma Research, SUNY Downstate Medical Center, Brooklyn, New York 11203, USA.   

 Correspondence to: Tamar A. Smith-Norowitz, Ph.D., SUNY Downstate Medical Ctr., Dept of Pediatrics, Box 49, 450 
Clarkson Ave., Brooklyn, New York 11203. (718) 270-1295; (718) 270-3289 (fax);  tamar.smith-norowitz@downstate.edu 
Received: 2009.05.07; Accepted: 2009.06.24; Published: 2009.06.30 
Abstract 
The role of the immune response in autoimmune hepatitis has not been studied before and 
after prednisone and azathioprine treatment. Distributions of blood lymphocytes (CD4+, 
CD8+, CD19+, CD23+, CD16/56+), levels of serum immunoglobulins (IgM, IgG, IgE, IgA) 
and cytokines (IFN-γ, IL-4, IL-12, TNFα ) were studied in a child (f/14 y/o) with autoimmune 
hepatitis before and after prednisone (20 mg/d) and azathioprine (50 mg/d) treatment 
(nephelometry, UniCAP Total IgE Fluoroenzymeimmunoassay, flow cytometry, cytokine 
ELISA). Patient was studied for 0-2.5 yrs; treatment was initiated 12 weeks post diagnosis. 
Numbers of CD4+ T cells increased (50%), while CD19+ and CD23+ cells decreased 
(>50%) post treatment; other lymphocyte subsets were unaffected by treatment. Serum IgG 
and IgE levels decreased (>50%) after treatment; serum IgM and IgA were within normal 
range and were not affected by treatment High levels of IFN-γ (5-23 pg/ml) were initially 
detected in serum, which decreased after treatment (<0.1 pg/ml). Furthermore, low levels of 
IL-4 (0.2 pg/mL) were detected before treatment, which were not detected after treatment 
(<0.1 pg/ml). In contrast, before treatment, IL-12 and TNFα were not detected in serum; 
however after treatment the levels of IL-12 and TNFα dramatically increased. Prednisone 
and azathioprine treatment decreased total serum IgG, IgE, IFN-γ and IL-4 levels, and blood 
CD19+ and CD23+ cells; however serum IL-12, TNFα and blood CD4+ T cells increased 
with treatment. Understanding immunomodulation in autoimmune hepatitis will provide 
better insight and mechanisms of this disease and may tailor more effective therapeutic in-
tervention. 
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INTRODUCTION 
Autoimmune liver disease in childhood includes 
Autoimmune Hepatitis (AIH) which is characterized 
by a chronic, immune-mediated liver inflammation 
involving mainly hepatocytes (1). Liver specific im-
mune reactivity in response to aberrant expression of 
antigen on the surface of hepatocytes is thought to be 
a major factor in development of AIH (2), and persis-
tent inflammation develops when these antigens are 
not eliminated (2). The major treatment options are 
immunosuppressive therapy, including steroids and 
azathioprine, which has proved effective; in most pa-
tients this disease has become treatable (1, 3). 
 It has been demonstrated that activation of CD8 
T cells occurs within the liver and causes liver in-
flammation. (4). T and B lymphocytes, macrophages, 
and plasma cells have been found in mononuclear cell Int. J. Med. Sci. 2009, 6 
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infiltrates that invade the surrounding parenchyma in 
patients with AIH (5). A defect in immunoregulation 
affecting CD4+CD25+ regulatory T cells (T-regs) has 
also been demonstrated in AIH (5). Increased num-
bers of IFN-gamma producing CD4 and CD8 T cells 
have been associated with biochemical evidence of 
liver damage, suggesting a combined cellular immune 
attack (5).   
 Liver disease has been considered a cause of IgE 
elevation (6). However, this may be related to the 
cause of liver injury, and not to liver disease. As such, 
studies of Minuk, et al (7) reported low serum im-
munoglobulin E (IgE) levels in patients with primary 
biliary cirrhosis (7). In contrast, chronic hepatitis C 
did not cause increased total serum IgE values (6). No 
data on serum IgE levels in AIH have been reported. 
 Therapy for AIH, as for other inflammatory liver 
disease, often includes immunosuppressive therapy 
such as azathioprine and steroids. The agents often 
work through immunomodulation due to decrease in 
activity of an aberrant immune response. However, 
the relationship of these agents on immunoglobulin 
and immune cell/subset responses are not well de-
fined.  
MATERIALS AND METHODS 
Patient history. 
 Peripheral blood (5 ml total) was obtained from 
a non atopic pediatric patient (f, 14 yrs old) from a 
private pediatric practice in Brooklyn, NY, who came 
to the office for her annual camp checkup. On physi-
cal examination she appeared well. Her height was 
153.5 cm and weight 55 kilograms. She did not have 
scleral icterus. Her chest was clear and abdomen soft 
with no evidence of hepatosplenoomegaly. Her vital 
signs were unremarkable, blood pressure of 108/70, 
heart rate of 86, temperature 97.3; respiratory rate was 
18 per minute. Prior checkups reported that the pa-
tient had always presented with normal growth and 
development and no recent illnesses.  
 Serologic results found serum aspartate ami-
notransferase (AST) and alanine aminotransferase 
(ALT) levels were elevated (Table I). Her other 
screening studies for chronic liver disease were nega-
tive including hepatitis A, B, and C serologies, Cy-
tomegalovirus and Epstein Barr virus. Her complete 
blood count (CBC) was relatively unremarkable. She 
had not received any medications or herbal agents. 
The patient was referred to The Mount Sinai Pediatric 
Liver Program (New York, NY) for evaluation, since 
the patient had a family history of liver disease. Ma-
ternal grandmother died of liver cirrhosis. A percu-
taneous liver biopsy revealed findings completely 
consistent with a diagnosis of type 1 autoimmune 
hepatitis. Patient was initially treated with prednisone 
therapy (20mg/d) and Pepcid. At 12 weeks post di-
agnosis, prednisone therapy was reduced to 15 mg/d, 
and immunosuppression treatment with azathioprine 
(Imuran) (75-100mg/d) was initiated, and then re-
duced to 50mg/d. She appeared to be responding 
well and was completely asymptomatic. She returned 
to the clinic every three-four months for routine 
laboratory (LFT) and therapeutic drug (Immuran 
metabolites) level monitoring. On her last visit (2.5 yrs 
post diagnosis), her prednisone was reduced from 
15mg to 10 mg once a day. The patient has done well 
for 4 years on the above therapy without evidence of 
symptoms or infections. 
Informed consent was obtained from the child’s 
parents and an assent form was signed by the subject, 
for the use of her blood/serum samples for an ex-
perimental study, which was drawn at various time 
points post initial diagnosis (e.g. 2 -18 weeks, 6-7 
months, 2.5 years).  
TABLE I. LIVER FUNCTION TEST RESULTS FROM A CHILD WITH AUTOIMMUNE HEPATITIS*   
  Liver Function Tests 
Time  AST ALT Bilirubin,  Total  Alkaline 
Phosphatase 
GGT Albumin  Globulin, 
calculated 
A/G ratio  INR 
  (2-35 U/L)  (2-40 U/L)  (0.2-1.3 mg/dL)  (60-350 U/L)  (2-60 U/L) (3.7-5.1 g/dL) (2.2-4.2 g/dL)  (0.8-2.0)  (0.90-1.10 Ratio)
0  45 73 0.8  179  nt 4.1  4.1  1  1.01 
2  wks  44 68 0.4  144  nt 4.0  4.6  0.9  1.01 
5 wks  60  104  0.5  121  79  4.0  4.6  0.9  1.17 
10  wks  38 64 0.5  92  75 4.2  4.6  0.9  nt 
18  wks  65 61 0.4  113  90 4.2  4.0  1.1  1.11 
6  mo  92 96 0.5  130  134  4.2  4.3  1.0  1.08 
7  mo  20 14 0.5  96  53 4.3  3.7  1.2  1.07 
2.5  yr  23 18 0.4  104  25 4.2  4.3  1.0  1.10 
*Liver function test results from a child with autoimmune hepatitis, as determined by Quest Diagnostics. Data are expressed as either mg/dl, 
g/dL, or U/ml. 
At 12 weeks post diagnosis, Prednisone (15 mg/d) and Azathioprine (Imuran, 50 mg/d) treatment was started.  
GGT: Gamma-glutamyl transpeptidase; INR: international normalized ratio 
nt: not tested Int. J. Med. Sci. 2009, 6 
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Symptoms and Diagnosis. 
  Patient was completely asymptomatic and was 
noted to have abnormal transaminases during routine 
blood tests for a camp checkup. A diagnosis of auto-
immune hepatitis was made on the basis of high se-
rum IgG levels (>2,000 mg/dL) (Table II), positive 
ANA (1:640), positive SMA (1:160), raised transami-
nases (AST, ALT, 40-70 U/L) (Table I), and interface 
hepatitis of moderate activity on liver biopsy, with 
Stage II to III fibrosis. Morphometric assessment of 
fibrosis was performed and correlated with 
METAVIR and Ishak semi quantitative score. The 
Diagnostic International Autoimmune Score (DIAS) 
was not reported. 
 
 
TABLE II. IMMUNOGLOBULIN LEVELS IN SERUM OF A 
CHILD WITH AUTOIMMUNE HEPATITIS*     
Day Immunoglobulin 
 IgM  IgG  IgA  IgE 
 (mg/dl)  (mg/dl)  (mg/dl)  (IU/ml) 
 
0 
 
83 
 
2250 
 
116 
 
54 
  
2 weeks 
 
94 
 
2540 
 
125 
 
49 
  
5 weeks 
 
105 
 
2630 
 
128 
 
44 
 
10 weeks 
 
179 
 
5520 
 
222 
 
36 
 
18 weeks 
 
93 
 
2340 
 
123 
 
26 
 
6 months 
 
79 
 
2080 
 
123 
 
25 
 
7 months 
 
78 
 
2120 
 
111 
 
22 
*Immunoglobulin levels in a child with autoimmune hepatitis, as 
determined by Quest Diagnostics (Nephelometry, ELISA). Data are 
expressed as either mg/dl or IU/ml.  
At 12 weeks post diagnosis, Prednisone (15 mg/d) and Azathio-
prine (Imuran, 50 mg/d) treatment was started. d: daily. 
Quest Diagnostics reference range for healthy child serum (ages 
3-18 y/o): IgM: 47-311 mg/dL; Total IgG: 688-1533 mg/dL; IgA: 
41-368 mg/dL; IgE: 20-100 IU/mL. 
 
 
Blood specimens. 
For studies of serum immunoglobulins (Ig), 
blood was collected into red top monoject tubes 
(Sherwood Medical, St. Louis, MO) and sent to Quest 
Diagnostics, Inc. for Ig determinations.  
Total Serum Immunoglobulins. 
Total serum immunoglobulins (IgM, IgG, IgA) 
were determined by Quest Diagnostics Inc. (Teter-
boro, NJ), using nephelometry - Quest Diagnostics 
reference range for healthy child serum (ages 3-18 
y/o): IgM: 47-311 mg/dL; Total IgG: 688-1533 mg/dL; 
IgA: 41-368 mg/dL. Total serum IgE levels were de-
tected by the UniCAP Total IgE Fluoroenzymeim-
munoassay (Pharmacia & Upjohn Diagnostics, Kala-
mazoo, MI) which was performed according to stan-
dard procedures. Data are expressed as International 
Units per milliliter (reference range for healthy child 
serum: IgE: 20-100 IU/mL.) 
Flow cytometry. 
For flow cytometry studies, blood was collected 
into ethylenediaminotetraacetic (EDTA) Monoject 
tubes (Sherwood Medical, St. Louis, MO) and retained 
for up to 2 hr at room temperature.  
Antibodies.  
Mouse anti-human monoclonal antibodies di-
rectly conjugated to fluorescein isothiocyanate (FITC) 
(IgG1 anti-CD23; IgM anti-CD60); phycoerythrin (PE) 
(IgG2a anti-CD45RO); Simultest 
(FITC/PE-conjugated) reagents (CD3/CD4, 
CD3/CD8, CD3/CD19, CD3/CD16+CD56), and ap-
propriately matched isotype control monoclonal an-
tibodies (FITC-conjugated IgG1, PE-conjugated IgG2a, 
Simultest control gamma1/gamma2a, FITC-conjugated 
IgM). All antibodies were purchased from BD Bio-
sciences, San Jose, CA, except IgM anti-CD60 which 
was purchased from Ancell, Bayport, Minn.; all were 
used according to manufacturers’ recommendation.  
Assay.  
Single and double labeling studies were carried 
out within 6 hr after blood was obtained. Conjugated 
antibodies (10 ul) (80 ul of titirated anti-CD60) di-
rected against 1-2 markers, were singly or simulta-
neously added to blood (100 ul) in a 12x75 mm (5 ml) 
tube (Fisher Scientific, Springfield, NJ) and incubated 
for 10 min at room temperature, after which erythro-
cytes were lysed with whole blood lysing reagent 
(Immunoprep, Beckman Coulter, Hialeah, FL), and 
the cells counted. Lymphocyte distributions were de-
termined on a Coulter Epics XL/MCL Flow Cytome-
ter using System II software (Coulter). CytoComp 
(Coulter) QC Windows (Flow Cytometry Systems, 
San Juan, Puerto Rico) were used to ensure consistent 
instrument settings. Forward and side scatter were 
used to identify the lymphocyte population, with 
CD45 used to establish an optimal lymphocyte gate. 
The gain on the photomultiplier tube detecting fluo-
rescence intensity was adjusted so that 99% of cells 
with background fluorescence staining were scored 
between 100-101 on a 4 decade log scale. Specific fluo-
rescence was reported as the percentage of cells with 
relative fluorescence intensity scored above back-Int. J. Med. Sci. 2009, 6 
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ground; at least 15,000 cells were counted per event. 
Absolute lymphocyte numbers are calculated from 
the total lymphocytes. Data are expressed as total 
lymphocytes per cubic millimeter (mm3) or mean 
percentage (%) of positive cells. 
Cytokine determination.  
Serum cytokines (IFN-γ, IL-4, IL-12, TNF-α) 
were determined by sandwich ELISA (Biosource, 
Camarillo, CA) according to the manufacturer’s pro-
tocol. Briefly, samples and standards were added to 
wells precoated with monoclonal murine antibodies, 
specific to human cytokines (IFN-γ, IL-4, IL-12, 
TNF-α) and incubated for 2 hr, after which a bio-
tin-conjugated polyclonal cytokine-specific conju-
gated streptavidin-HRP antibody (100ul) (Biosource) 
was added, and incubated for 1 hr. Plates were 
washed three times, after which TMB substrate was 
added (100 ul) and incubated for 15 min. The reaction 
was terminated with 1N H2S04 stop solution (100ul). 
Plates were read using an automated microplate 
reader (Model Elx800; Bio-Tek Instruments, Winooski, 
VT), Absorbance was read at 450 nm within 30 min 
and sample concentrations were determined based on 
the standard curve. Data are reported as pg/ml. 
 
RESULTS 
1. Liver function tests.  
Laboratory evaluation results for liver function 
tests were within normal ranges, except for elevated 
AST and ALT levels. After treatment with azathio-
prine, these levels eventually decreased to normal 
levels (7 mo) (Table I). 
2. Serum immuoglobulins. 
 Total IgM, IgG, IgA, and IgE. Serum obtained 
from patient contained normal levels of total IgM and 
IgA, but increased levels of total IgG (Table II). Total 
IgG levels were highest at 10 weeks post diagnosis, 
and decreased 2-fold (50%) after treatment with 
azathioprine. Total serum IgE levels also decreased 
50% after treatment with asathioprine, but were 
within normal range (<100 IU/mL). Total IgM and 
IgA levels w ere w ithin  n ormal range (see materials 
and methods) and were not affected by treatment 
(Table II). 
3. Distributions of blood lymphocyte subpopula-
tions. 
Distributions of lymphocyte subpopulations 
(CD3+CD4+, CD3+CD8+, CD8+CD60+, 
CD16+CD56+, CD19+) in peripheral blood of our pa-
tient were studied. The percentage of CD4+ T cells 
increased (50%), while CD19+ and CD23+ cells de-
creased (>50%) post treatment; other lymphocyte 
subsets were unaffected by treatment (Table III).  
 
4. Cytokines in serum.  
High levels of IFN-γ (5-23 pg/ml) were initially 
detected in serum, which decreased after treatment 
(<0.1 pg/ml). Furthermore, low levels of IL-4 (0.2 
pg/mL) were detected before treatment, which were 
not detected after treatment (<0.1 pg/ml). Before 
treatment, IL-12 and TNFα were not detected in se-
rum (<0.1 pg/ml); however after treatment the levels 
of IL-12 and TNFα dramatically increased (~2-fold) 
(data not shown). 
 
 
 
TABLE III. DISTRIBUTIONS OF LYMPHOCYTE SUBPOPULATIONS IN PERIPHERAL BLOOD OF A CHILD WITH 
AUTOIMMUNE HEPATITIS* 
Day CD3+CD4+ CD3+CD8+  CD8+CD60+  CD16+56+  CD19+  CD23+ 
 (%)  mm3 (%)  mm3 (%)  mm3 (%)  mm3 (%)  mm3 (%)  mm3 
0  28  382  14 194 11  145 8  108 44  598 26  350 
2  weeks  36  368 15  152  9  98 7  75 36 375  18 187 
6  mo 38  409 20  221  19 200  9  95 24 263  15 159 
7 mo  41  339  23  187  18  149  7  57  17  142  9  73 
2.5  yrs  56  393  16 114 13  88  qns qns 15  108 3  21 
* The distributions of lymphocyte subpopulations in peripheral blood of a child with autoimmune hepatitis was determined, by flow mi-
crofluorimetry (Coulter Epics XL/MCL). Data are expressed as mean total cells/mm3 or mean percentage (%) of positive cells. At 12 weeks 
post diagnosis, Prednisone (15 mg/d) and Azathioprine (Imuran, 50 mg/d) treatment was started. 
qns: quantitiy not sufficient; d: daily. 
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DISCUSSION 
The present studies are the first to describe the 
immune response in autoimmune hepatitis before and 
after prednisone and azathioprine treatment. We 
found that prednisone and azathioprine treatment 
decreased total serum IgG, IgE, IFN-γ and IL-4 levels, 
and blood CD19+ and CD23+ cells; however serum 
IL-12, TNF-α and blood CD4+ T cells increased with 
treatment.  
AIH is a necroinflammatory liver disease of un-
known etiology that occurs in children and adults (8); 
patients are predominantly female (9). Characteristics 
include its autoimmune features, hyperglobulinemia 
(IgG), and the presence of circulating autoantibodies, 
as well as response to immunosuppressive drugs (9). 
Clinical manifestations are variable, ranging from 
asymptomatic disease to hepatic failure that requires 
liver transplantation (8, 9). Patients may present with 
non-specific symptoms including fatigue, lethargy, 
nausea and abdominal pain (8, 9). Hepatitis with ele-
vation of AST and ALT levels usually leads to a di-
agnosis of AIH (9). Since there is no one test which 
proves the diagnosis of AIH, a liver biopsy remains 
important (9). 
Immunosuppressive therapy with corticoster-
oids, usually in combination with azathioprine is 
considered standard protocol to induce and maintain 
remission (9). Response to immunosuppressive ther-
apy also confirms the diagnosis of AIH (10).This was 
observed in our study. Alternative immunosuppres-
sive therapies have been proposed including cyc-
losporine followed by the administration of predni-
sone and azathioprine (11-12). Recent studies have 
shown that budenoside has also been proven to be an 
efficacious alternative to prednisone (13).  
AIH is a disease of autoreactivity that reflects 
multiple disturbances in the counter-regulatory 
mechanisms essential for immune homeostasis; the 
number and function of T regulatory cells and natural 
killer cells are affected (14). The triggering epitope is 
thought to be a short sequence peptide that is com-
mon among multiple infectious agents (14). Other 
liver disorders in childhood include autoimmune 
sclerosing cholangitis (ASC) and de novo AIH after 
liver transplantation, which have symptoms reminis-
cent of classical AIH, including elevated titers of se-
rum antibodies (15).   
 In the present study, our patient had elevated 
serum IgG levels. Treatment with prednisone and 
azathioprine decreased total serum IgG and IgE lev-
els, and blood CD19+ and CD23+ cells, while blood 
CD4+ T cell increased after treatment. This may be 
due to the selective responses of immunosuppressive 
agents when administered as different combined 
therapy regimens with respect to the disease. In this 
regard, studies of BravoSoto et al, ( 1 6 )  h a v e  s h o w n  
that CD19+ cells are reduces in renal allograft patients 
after treatment with azathioprine, prednisone and 
cyclosporine A (16). However in those studies CD3(+), 
CD3(+)CD4(+), CD3(+)CD8(+), were also reduced in 
kidney transplant patients (16), whereas in our studies 
these cells either increased (CD3+CD4+) or remained 
the same (CD3(+)CD8(+)). It is possible that the addi-
tion of cyclosporine may have additional immuno-
modulatory effects. Differences in immunosuppres-
sive therapy, which may also include intravenous 
immune globulin, undoubtedly moderates the im-
mune system and these responses are likely disease 
specific.  
Autoreactive immune responses are controlled 
on multiple levels (17): including deletion of autore-
active T cells in the thymus (18), and the presence of 
regulatory antiidiotypic and anticlonotypic cellular 
networks in the control of autoreactive T cells as well 
as T cells responsive to the activation state (19-21). It is 
unknown whether the anticlonotypic T-cell response 
is directed to T-cell receptor molecules and what these 
cells functions are in AIH (22).  
Studies of Lohr, et al. described a CD4+ T-cell 
epitope in AIH that was recognized by Th1 helper 
cells isolated from blood and liver tissue (23). This 
autoreactive T-cell response correlated with disease 
activity (23). In vitro studies have reported that most 
of the liver-infiltrating T cells in AIH are CD4+CD8- 
and secrete IFN-γ and TNF-α after mitogenic activa-
tion, although the relative proportion of Th2 –helper 
cells was increased (23-24). Studies of Mix, et al iden-
tified in mice, CD4 T-cell epitopes in soluble anti-
gen/liver pancreas autoantigen in AIH (25). How-
ever, autoreactive T cells in AIH patients in clinical 
studies have not been studied (25) and T cell profiles 
have not been monitored in AIH patients before and 
after treatment with prednisone and azathioprine.  
In our study, AIH appears to be mediated by 
cellular immune responses, specifically CD4+ T cells. 
This is in agreement with earlier studies (26-27) that 
demonstrated immunohistological data of lympho-
cyte infiltrations consist of CD3+CD4+ T cells, and 
increased expression of HLA class I and II molecules.  
It has been reported in AIH that T cells primarily 
released Th-1 type cytokines, but the frequency of 
Th-2 type cells producing IL-4 was increased (24). 
Others have shown in hepatitis C infection serum 
soluble CD23, but not IL-8, IL-10, GM-CSF, or IFN-γ is 
elevated (28). In our study, we found that prednisone 
and azathioprine treatment decreased total serum 
IFN-γ and IL-4 levels; however serum IL-12, and Int. J. Med. Sci. 2009, 6 
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TNF-α increased with treatment. Studies by Hassan et 
al. (29) have also demonstrated decreased IFN-γ levels 
in the supernatants of cultured peripheral lympho-
cytes obtained from kidney transplant patients im-
munosuppressed with cyclosporine A, corticosteroids 
and azathioprine, whereas IL-4 levels did not show 
significant changes. These observed differences in 
azathioprine responses might be due to differences in 
treatment approaches which often employ multidrug 
treatment regiments. Furthermore, these responses 
are likely disease specific.  
The immunopathogenesis of autoimmune liver 
disease is not clearly understood (22). We describe a 
case of AIH in a patient treated with prednisone and 
azathioprine, where we compared Ig and lymphocyte 
profiles before and after treatment. Further studies are 
warranted to further elucidate immune responses in 
AIH, with respect to treatment regiments, which can 
determine disease responses and guide immunosup-
pressive therapy. 
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